NeOnc Technologies Holdings, Inc. Common Stock (NTHI)vsRevolution Medicines Inc (RVMD)
NTHI
NeOnc Technologies Holdings, Inc. Common Stock
$3.49
+9.06%
HEALTHCARE · Cap: $100.53M
RVMD
Revolution Medicines Inc
$192.28
+8.24%
HEALTHCARE · Cap: $40.45B
Smart Verdict
WallStSmart Research — data-driven comparison
Revolution Medicines Inc generates 1755% more annual revenue ($742,000 vs $39,990). RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).
NTHI
Avoid14
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
0.0% margin — thin
Trading at 15.8x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : NTHI
The strongest argument for NTHI centers on Debt/Equity.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : NTHI
The primary concerns for NTHI are EPS Growth, Market Cap, Return on Equity.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
RVMD is growing revenue faster at -95.2% — sustainability is the question.
NTHI generates stronger free cash flow (-5M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RVMD scores higher overall (24/100 vs 14/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
NeOnc Technologies Holdings, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
NeOnc Technologies Holdings, Inc. is a pioneering biotechnology firm dedicated to revolutionizing cancer treatment through its advanced immunotherapy and molecular medicine initiatives. The company boasts a compelling pipeline of innovative product candidates aimed at addressing critical unmet needs within oncology, which positions it as a potential leader in the evolution of cancer care. Backed by strategic partnerships within the biopharmaceutical sector, NeOnc has the capability to accelerate the commercialization of its groundbreaking therapies, presenting a compelling opportunity for institutional investors interested in the expanding cancer therapeutics market.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?